Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 36

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
,719 Changes in operating assets and liabilities:Accounts receivable(3,563)(3,579)Inventories4,731 1,990 Prepaid expenses and other assets7,372 (7,517)Accrued product returns and rebates1,428 12,952 Accounts payable and other liabilities3,938 10,019 Net cash provided by operating activities30,599 38,401 Cash flows from investing activitiesPurchases of marketable securities(118,557)(193,700)Maturities of marketable securities156,201 142,324 Purchases of property and equipment(327)(248)Net cash provided by (used in) investing activities37,317 (51,624)Cash flows from financing activitiesProceeds from issuance of common stock2,042 2,910 Employee taxes paid related to net share settlement of equity awards(3,341)(1,340)Payment of contingent consideration(20,100)— Net cash provided by (used in) financing activities(21,399)1,570 Net change in cash and cash equivalents46,517 (11,653)Cash and cash equivalents at beginning of year69,331 75,054 Cash and cash equivalents at end of period$115,848 $63,401 Supplemental cash flow informationCash paid for income taxes$274 $336 Cash paid for operating leases$3,892 $4,002 Noncash investing and financing activitiesLease assets obtained for new operating leases— 2,604 See accompanying notes.

7

Supernus Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

1.    Business Organization

Supernus Pharmaceuticals, Inc. (the Company, see Consolidation in Note 2, Summary of Significant Accounting Policies) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.The Company has eight commercial products that it markets: Qelb